Inflammation as a therapeutic target in heart failure? A scientific statement from the Translational Research Committee of the Heart Failure Association of the European Society of Cardiology
Experimental & Molecular Cardiology, Cardiovascular Research Institute Maastricht (CARIM), Maastricht University, Universiteitssingel 50, 6229 ER Maastricht, The Netherlands
* Corresponding author. Tel: +31 43 3877097, Fax: +31 43 3871055, Email: s.heymans{at}cardio.unimaas.nl
 |
Abstract |
|---|
The increasing prevalence of heart failure poses enormous challenges for health care systems worldwide. Despite effective medical interventions that target neurohumoral activation, mortality and morbidity remain substantial. Evidence for inflammatory activation as an important pathway in disease progression in chronic heart failure has emerged in the last two decades. However, clinical trials of ‘anti-inflammatory’ therapies (such as anti-tumor necrosis factor-
approaches) have to date failed to show benefit in heart failure patients. The Heart Failure Association of the European Society of Cardiology recently organized an expert workshop to address the issue of inflammation in heart failure from a basic science, translational and clinical perspective, and to assess whether specific inflammatory pathways may yet serve as novel therapeutic targets for this condition. This consensus document represents the outcome of the workshop and defines key research questions that still need to be addressed as well as considering the requirements for future clinical trials in this area.
Key Words: Inflammation • Heart failure • Treatment
Received November 9, 2008; Accepted December 10, 2008
See page 111 for the editorial comment on this article (doi:10.1093/eurjhf/hnf039)
CiteULike 
Connotea 
Del.icio.us What's this?
Related articles in Eur J Heart Fail:
- Inflammation in chronic heart failure: what is familiar, what is unfamiliar?
- Michael Fu
Eur J Heart Fail 2009 11: 111-112.[Extract] [Full Text]
This article has been cited by other articles:
|
|
 |
|
  J. F. Lula, M. O. d. C. Rocha, M. d. C. P. Nunes, A. L. P. Ribeiro, M. M. Teixeira, M. T. Bahia, and A. Talvani Plasma concentrations of tumour necrosis factor-alpha, tumour necrosis factor-related apoptosis-inducing ligand, and FasLigand/CD95L in patients with Chagas cardiomyopathy correlate with left ventricular dysfunction Eur J Heart Fail, September 1, 2009; 11(9): 825 - 831. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. A. Pascual-Figal, J. C. Bonaque, B. Redondo, C. Caro, S. Manzano-Fernandez, J. Sanchez-Mas, I. P. Garrido, and M. Valdes Red blood cell distribution width predicts long-term outcome regardless of anaemia status in acute heart failure patients Eur J Heart Fail, September 1, 2009; 11(9): 840 - 846. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Fu Inflammation in chronic heart failure: what is familiar, what is unfamiliar? Eur J Heart Fail, February 1, 2009; 11(2): 111 - 112. [Full Text] [PDF]
|
|